Market Overview

Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Share:
Related IDXX
Earnings Scheduled For January 29, 2016
Worst Performing Industries For October 28, 2015
Related NEOG
Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Steelcase Shares Dip Following Weak Results
Mid-Morning Market Update: Markets Open Higher; Neogen Earnings Miss View

Below are the top diagnostic substances stocks on the NASDAQ in terms of revenue estimate for the current year.

Analysts expect IDEXX Laboratories (NASDAQ: IDXX) to post revenue of $1.30 billion for the year ending December, 2012. IDEXX had $221.44 million in total cash for the latest quarter.

Neogen (NASDAQ: NEOG) is likely to post revenue of $205.21 million in the year ending May, 2013. Neogen's trailing-twelve-month operating margin is 19.11%.

Meridian Bioscience (NASDAQ: VIVO) is expected to report revenue of $189.80 million for the year ending September, 2013. Meridian Bioscience's trailing-twelve-month ROE is 23.73%.

Abaxis (NASDAQ: ABAX) may report revenue of $182.77 million in the year ending March, 2013. Abaxis' PEG ratio is 3.40.

Posted-In: Diagnostic Substances Industry Highest Revenue Estimates NASDAQ StocksTrading Ideas

 

Related Articles (ABAX + IDXX)

Get Benzinga's Newsletters